| Project/Area Number |
20590924
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
ISHIKAWA Nobuhisa Hiroshima University, 大学院・医歯薬学総合研究科, 助教 (90423368)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
NOBUOKI Kohno 広島大学, 大学院・医歯薬総合研究科, 教授 (80215194)
HATTORI Noboru 広島大学, 大学院・医歯薬総合研究科, 准教授 (00283169)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2008: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | 肺癌 / 肺線維症 / 慢性閉塞性肺疾患 / ムチン / バイオマーカー / 人種差 / 肺がん |
|---|
| Research Abstract |
The circulating levels of KL-6 and SP-D in European were higher than those in Japanese control subjects suggesting that the cut-off level for these biomarkers in the European are probably higher than in the Japanese population.We demonstrated that pretreatment serum levels of KL-6 can serve as an independent prognostic factor for NSCLC patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI) in a large multi-institutional setting. We also showed that among NSCLC patients with wild-type EGFR, progression free survival (PFS) was significantly shorter in patients with high serum KL-6 levels than in patients with normal serum KL-6 levels.
|
